Sumitomo Mitsui Trust Group
NRIX icon

Sumitomo Mitsui Trust Group’s Nurix Therapeutics NRIX Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$20.5M Sell
863,077
-120,385
-12% -$3M 0.01% 596
2026
Q2 		$23.9M Sell
983,462
-197,684
-17% -$3.37M 0.01% 607
2026
Q1 		$18.3M Sell
1,181,146
-109,408
-8% -$1.81M 0.01% 627
2025
Q4 		$24.5M Sell
1,290,554
-266,925
-17% -$3.83M 0.01% 615
2025
Q3 		$14.4M Buy
1,557,479
+165,841
+12% +$1.72M 0.01% 660
2025
Q2 		$15.9M Buy
1,391,638
+635,668
+84% +$6.87M 0.01% 644
2025
Q1 		$8.98M Sell
755,970
-33,252
-4% -$556K 0.01% 698
2024
Q4 		$14.9M Buy
789,222
+235,971
+43% +$5.41M 0.01% 679
2024
Q3 		$12.4M Buy
+553,251
New +$12.5M 0.01% 691

Other funds holding NRIX

WestHill Financial Advisors
WestHill Financial Advisors San Rafael, California $597M AUM 13.09% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
RAM Investment Partners
RAM Investment Partners Bellevue, Washington $631M AUM 11.73% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

Sumitomo Mitsui Trust Group's NRIX Position: Q3 2026 in Review

Sumitomo Mitsui Trust Group reduced its Nurix Therapeutics (NRIX) stake by 12% in Q3 2026, selling an estimated $3M and leaving 863,077 shares worth $20.5M. The position accounts for 0.01% of the portfolio, ranked #596.

Sumitomo Mitsui Trust Group first reported a position in NRIX in Q3 2024 and has held it in 9 quarters since. The position peaked at $24.5M in Q4 2025. 37 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • Sumitomo Mitsui Trust Group held 863,077 shares of Nurix Therapeutics worth $20.5M as of Q3 2026.
  • Sumitomo Mitsui Trust Group sold 120,385 Nurix Therapeutics shares in Q3 2026, an estimated $3M.
  • Nurix Therapeutics made up 0.01% of Sumitomo Mitsui Trust Group's portfolio in Q3 2026, its #596 holding.
  • Sumitomo Mitsui Trust Group first reported a position in Nurix Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • Sumitomo Mitsui Trust Group's Nurix Therapeutics position peaked at $24.5M in Q4 2025.
  • 37 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q3 2026, filed 29 Oct 2026.